acalabrutinib
Showing 26 - 50 of 86
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,
Terminated
- Diffuse Large B Cell Lymphoma
- +3 more
- Acalabrutinib
- +4 more
-
Miami, FloridaUniversity of Miami
Aug 23, 2022
Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 8, 2022
Chronic Lymphocytic Leukemia Trial in Poland, United Kingdom (Ceralasertib, Acalabrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ceralasertib
- Acalabrutinib
-
Kraków, Poland
- +10 more
Dec 2, 2022
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- Acalabrutinib
- Duvelisib
- (no location specified)
Jun 2, 2022
Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)
Recruiting
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- Durvalumab
- Acalabrutinib
-
Saint Louis, MissouriWashington University School of Medicine
Mar 14, 2022
Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)
Suspended
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
Food Allergy, Food Allergy Peanut Trial in Baltimore (Acalabrutinib)
Recruiting
- Food Allergy
- Food Allergy Peanut
- Acalabrutinib
-
Baltimore, MarylandJohns Hopkins Bayview Medical Center
Dec 30, 2021
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in
Recruiting
- Autoimmune Hemolytic Anemia
- +3 more
- Acalabrutinib
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 9, 2022
Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Feb 2, 2022
Mantle Cell Lymphoma Trial in Canada (Acalabrutinib, R-CHOP chemo)
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- R-CHOP chemotherapy
-
Vancouver, British Columbia, Canada
- +3 more
Mar 17, 2022
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Rochester (Acalabrutinib, Rituximab)
Active, not recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Acalabrutinib
- Rituximab
-
Rochester, New YorkUniversity of Rochester
Feb 7, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Acalabrutinib
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jun 16, 2022
Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphoid Leukemia
- Bendamustine
- +3 more
-
Dresden, Germany
- +16 more
Nov 8, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Acalabrutinib, Obinutuzumab)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Basking Ridge, New Jersey
- +7 more
Nov 9, 2022
Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)
Active, not recruiting
- Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
- Acalabrutinib
-
Los Angeles, California
- +6 more
Dec 1, 2022
Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II
Active, not recruiting
- Phase I: Relapsed or Refractory B-cell Malignancies
- +2 more
- Acalabrutinib
-
Beijing, China
- +22 more
Dec 8, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial in Columbus (acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- acalabrutinib
- +3 more
-
Columbus, OhioResearch Site
Mar 11, 2022
Mantle Cell Lymphoma Trial in New York (Acalabrutinib, Lenalidomide, Rituximab)
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
New York, New YorkWeill Cornell Medicine
Oct 29, 2021
Healthy Volunteers Trial in Tempe (Acalabrutinib, Fluconazole, Isavuconazole)
Completed
- Healthy Volunteers
- Acalabrutinib
- +2 more
-
Tempe, ArizonaCelerion
Nov 17, 2021
Chronic Lymphocytic Leukemia Trial in Columbus, Hermitage, Fort Worth (acalabrutinib, ACP-319)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- acalabrutinib
- ACP-319
-
Columbus, Ohio
- +1 more
Jan 20, 2022